Expose Hidden Corporate Lobbying By Eli Lilly
Despite saying it supported lower drug prices, Eli Lilly spent tens of millions of dollars lobbying over the last decade — including fighting against legislation to reduce the price of insulin and other life-saving prescription drugs. Now, a group of shareholders have filed a proposal that would make Eli Lilly be fully transparent about its lobbying activities and reveal whether its behind-closed-doors lobbying matches its public statements.
This lobbying transparency proposal will be voted on at Eli Lilly’s annual shareholder meeting on May 6, 2024.